The CEO of Cellceutix Corporation (OTCQB: CTIX), a preclinical cancer, anti-inflammatory and autism drug developer says his company’s leading drug candidate, Kevetrin, is a new class of chemistry in medicine which has proven to this point to restore p53 (also known as the “Guardian Angel” gene ) back to a normal status so it can do its job as master regulator and see to it that the cancer cells are destroyed without damaging any DNA.

Cellceutix has been in the news and attracting investor attention lately as developments with Kevetrin as a novel indication for a variety of drug-resistant cancers nears clinical trials after producing strong pre-clinical data.

Leo Ehrlich, CEO of Cellceutix, tells BioMedReports in an exclusive interview that p53 is a key component in regulating the cell cycle.

“In more than half of all cancers, the p53 has lost all or a portion of its function which allows cancer cells to run rampant,” explains Ehrlich. “Researchers have known about the p53 correlation to carcinomas, but have yet been able to come-up with a solution to restore the function of p53. There was a class of drugs called ‘Nutlins’ a few years ago that believed to hold promise, but proved to be genotoxic — meaning that the drug damaged the host’s DNA — so that quickly was realized as not a viable option. Kevetrin has proven to this point to restore p53 back to a normal status so it can do its job as master regulator and see to it that the cancer cells are destroyed without damaging any DNA.”

The full exclusive interview with Ehrlich on the significance of his company’s drug compound, including more details about the drug candidate’s clinical trial at a major cancer center is available now at:

http://biomedreports.com/2011072670602/ceo-cellceutix-leading-drug-candidate-represents-major-breakthrough-in-cancer-research.html

In addition, investors interested in accessing BioMedReports’ new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades can go to:

http://biomedreports.com/access-our-exclusive-fda-and-clinical-trials-calendars.html

News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com

Media Contacts Only:

Mary Davila
Assistant Editor
www.BioMedReports.Com
Tel: +1 323 472 4480
Fax: +1 888 210 3556

Cellceutix (CTIX) Stock Quote and News:

---

Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated on several occasions for news dissemination and journalism services from Cellceutix Corporation and holds a total of 100,000 shares of 144 restricted stock of Cellceutix Corporation, none of which has been sold to date, nor intends to be sold in the near term. Prior compensation is listed in our full disclosure. Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.